Biotage has launched a purification technology, Accelerated Chromatographic Isolation (ACI), which converts simple flash purification into a faster and more economical way to isolate pure compounds.
Biotage, a supplier of solutions and technology for analytical, medicinal and peptide chemistry, has launched a purification technology, Accelerated Chromatographic Isolation (ACI), which converts simple flash purification into a faster and more economical way to isolate pure compounds.
According to Biotage, ACI has the potential to improve chromatography efficiency in the laboratory. ACI can move users to the endpoint faster. Traditional purification takes more than 15 minutes. With ACI, the time is reduced to 5 minutes. A 250-mg scale laboratory experiment can now be purified in less than 3 minutes on a 10 g column with an ACI enabled Biotage Isolera flash purification system.
"Chemists will now have freedom to work on other things while they let their ACI system do the purification. It is fully automated, reliable and lightning fast, we can completely purify 250 mg of sample in less than 3 minutes, this is quicker than most people take to run the TLC," said Sunil Rana, global product manager, Biotage, in a press release.
Biotage Isolera systems recommend cartridges based on the sample size and programed TLC data; they work out the best solvent gradient based on compound, and provide real time indication of eluting compounds, using UV, ELSD or mass detection. They subtract signal baselines automatically so that chemists can be confident that the correct fractions are collected.
ACI works seamlessly with the Biotage Isolera system. The simple wizard quickly guides chemists through the system, beneficial for new users or those whose expertise or priorities lie in synthesis rather than purification. Existing Biotage Isolera systems can be upgraded to ACI systems. ACI will come as standard on all new production systems.
Source: Biotage
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.